| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4cd07c824767e0e7a22c44bf6a785d01 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D497-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D513-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 |
| filingDate |
2018-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_98c16346a7f925e768e4193db7e31e21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6946829ba10f6b8029db57b7bfc9a708
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_149f931cbabf924f9b02a17c18099b5e |
| publicationDate |
2018-11-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
TW-201839000-A |
| titleOfInvention |
Thiamine derivative as an A2A inhibitor and method for treating cancer |
| abstract |
The present invention relates to a compound of formula I (I) or a pharmaceutically acceptable salt or solvate thereof. The invention further relates to the use of a compound of formula I as an A2A inhibitor. The invention also relates to the use of a compound of formula I for the treatment and/or prevention of cancer. The invention also relates to a process for the manufacture of a compound of formula I. |
| priorityDate |
2017-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |